Serology of hepatitis B virus: multiple scenarios and multiple exams

INTRODUCTION

The hepatitis B virus (HBV) is a health problem throughout the world. It is estimated that 2000 million people have been exposed to the virus and that 240 million are chronically infected making it the most frequent chronic viral infection of all. (1, 2) Between 15% an 40% of those with chronic infections progress to cirrhosis and its complications, including hepatocellular carcinoma. (3) In 2013, HBV produced 686,000 deaths, (3) an increase of 33% from 1990 to 2013. (3) In 2005, HBV prevalence in Central America was less than 2% and in South America it was 2% to 4%, (3) but in South America there are now 400,000 new cases each year. (3) Despite recommendations for universal vaccination against HBV, this prophylaxis has not been widely implemented in the countries with the highest prevalences due to lack of economic and logistical resources. (3)

HBV is a hepatotropic virus with an external envelope and a member of the Hepadnaviridae family of small deoxyribonucleic acid (DNA) viruses (3,200 base pairs). (4, 5) Its DNA is partially double-stranded and partially single-stranded, and it has a transcriptional template that is covalently closed circular DNA (cDNA) which is introduced very rapidly into the nucleus of the hepatocyte during acute infection. (6) It belongs to the genus Orthohepadnavirus which infects mammals and the genus Avihepadnaviridae which affects birds (4). It is thought that this virus originated in Africa at least 40,000 years ago. (6) It has 10 genotypes (A-J), A is frequent in North America, Northern Europe and Africa while B and C occur frequently in Asia. (4, 7) Some studies have found associations between the genotype, progression of the disease, and response to interferon. (4) Genotypes C and F are more frequently associated with hepatocellular carcinoma as well as some subgenotypes of type A. On the other hand, genotype A is associated with risk of progression to chronic infection. (4, 7) Nevertheless, any acute infection regardless of genotype can progress to a chronic infection. (4)

HBV is primarily transmitted through sexual, perinatal, or mucosal routes or through percutaneous parenteral rou-
tes resulting from injuries with sharp elements contaminated with infected blood. (8) This last form of transmission includes accidental punctures in hospital environments with contaminated surgical instruments, manicure procedures, pedicures, tattoos, intravenous drug abuse (sharing contaminated syringes) and piercings. (8) Infections from these procedures has decreased as the risks inherent to them have become known, sterilization of medical instruments has been implemented, and reuse of needles has been banned. (9) Sexual transmission has been reduced by education about the use of sexual protection measures. (8, 9) Ninety-five percent of cases of vertical transmission occur during vaginal deliveries and 5% occur through intrauterine transmission. (8) The clinical spectrum of HBV infection includes acute hepatitis, chronic hepatitis and occult infections. (10) Similarly, HBV can cause cirrhosis, hepatocellular carcinoma and can compromise extrahepatic organs. (11-14)

Due to the impact and complexity of HBV infections, this review discuss the various tests used to diagnose the infection in scenarios found in daily practice (Figure 1).

**Figure 1.** Scenarios for HBV serology

**ACUTE HEPATITIS B**

The diagnosis of acute Hepatitis B is confirmed by a positive blood test for HBV surface antigen (HBsAg) and IgM antibody to hepatitis B core antigen (anti-HBc IgM). (15) HBsAg is the serological marker of HBV infections, (15) but there are cases in which HBsAg disappears rapidly without the appearance of HB surface antibodies. This is the immunological window period in which the only evidence of acute infection with HBV is the IgM antibody. (15) HB surface antibodies appears two weeks after HBsAg and may persist for up to two years. (16) HBsAg is detectable from one week to ten 10 weeks after contact. (2) Detection of anti-HBC IgM coincides with development of general symptoms and increasing aminotransferases. (14)

The resolution of acute hepatitis is characterized by disappearance of HBsAg, appearance of anti-HBsAg antibodies, anti-HBc immunoglobulin G (IgG) and normalization of alanine-aminotransferase (ALT) levels. (14, 15) This profile indicates apparent cure and has been defined as functional healing. (17) Nevertheless, it has been found that despite markers of disappearance of the infection, cDNA persists in the nucleus of the hepatocyte as an episome or minichromosome from which ribonucleic acid (RNA) and this DNA are generated to initiate replication viral. (18). This cDNA remains in the host indefinitely after the first 24 hours of infection. (18) Replication from this reservoir of HBV can restart if immune defense mechanisms are blocked, as occurs with immunosuppression since host immunity controls those infected cells. (19)

Recently, the concept of a functional cure has been redefined as the loss of HBsAg with or without the appearance of anti-HBsAg antibody or any HBV DNA detectable in serum, but with the persistence of cDNA. (6, 13) In contrast, a total cure is functional healing plus elimination of cDNA. (20, 21) At present, it is impossible to cure HBV infections because the available drugs only suppress viral replication but cannot eliminate cDNA. (19, 22) The elimination of cDNA is the ideal goal of treatment of chronic HBV infections. (6, 19)

Tests for IgM anti-HBc are positive in 10% to 15% of patients whose chronic HBV infections have reactivated and are indistinguishable from acute infections. (15, 16, 23, 24) Nevertheless, other serological characteristics can help differentiate them. In acute infections, the IgM is pentameric and has a molecular weight of 19 S, but in chronic infections, the IgM is monomeric and has a molecular weight of 7 to 8 S. (16) Titers greater than 1:1,000 are seen in 80% of acute infections with a sensitivity of 96.2% and a specificity of 93.1% when determined by enzyme immunoassay. (23) IgM titres less than 1:1,000 are seen in 70% of acutely exacerbated chronic hepatitis B cases. (23, 24)

**CHRONIC HEPATITIS B**

An HBV infection is chronic when tests for HBsAg continue to be positive for 6 months after an acute infection is diagnosed. (8, 9, 14) Whether HBV will become chronic depends on the interaction between HBV and the immune system, but the probability increases in cases of with immature immune system and immunosuppressed patients. (25) Ninety-eight
percent of HBV cases in newborns become chronic, while twenty to thirty percent of cases among children from one to five years of age become chronic. In contrast, less than 5% of cases in immunocompetent adults become chronic. (26, 27) A summary of interpretations of findings from HBV serology is shown in Table 1.

<table>
<thead>
<tr>
<th>Table 1. Typical HBV serology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HBsAg</strong></td>
</tr>
<tr>
<td>Acute infection</td>
</tr>
<tr>
<td>Infection resolved</td>
</tr>
<tr>
<td>Chronic infection</td>
</tr>
<tr>
<td>Vaccinated</td>
</tr>
<tr>
<td>Susceptible</td>
</tr>
</tbody>
</table>

* Hepatitis B surface antibodies

The European Association for the Study of the Liver (EASL) classifies chronic hepatitis B into 4 types according to positivity for the “e” antigen and the presence or absence of liver disease (Table 2). (28) This new classification replaces the previous nomenclature of expressions including inactive carrier and immunotolerance.

Treatment is indicated in the following situations: (28)

1. Any patient who has chronic hepatitis defined by DNA> 2000 IU/mL and whose ALT is above the upper limit of normal and/or has moderate hepatic necroinflammation or fibrosis) with or without the “e” antigen.
2. Any patient with compensated or decompensated cirrhosis, regardless of the levels of DNA and ALT.
3. Any patients with DNA> 20,000 IU/mL and ALT two times the upper limit of normal, regardless of the degree of fibrosis.
4. Any patient older than 30 years who tests positive for the “e” antigen and has chronic infection and high DNA, levels but persistently normal ALT levels, regardless of the severity of liver histology.

5. Any patient with a chronic infection whether or not they test positive for the “e” antigen, who has a family history of hepatocellular carcinoma or cirrhosis with extrahepatic manifestations, even though she/he does not meet the typical indications for treatment.

It is recommended that patients with chronic hepatitis B who do not meet the treatment criteria be periodically checked:

1. Patients who are under 30 years of age who test positive for the “e” antigen should be monitored every 3 to 6 months.
2. Patients whose tests are negative for the “e” antigen and whose HBV DNA count is less than 2,000 IU/mL should be monitored every 6 to 12 months. If HBV DNA level is over 2,000 IU/mL, they should be monitored every 3 months for the first year and every 6 months thereafter.

**OCCULT HBV INFECTIONS (OBIS)**

The existence of OBIs was first suspected in the 1970s, but the first publication on the subject was produced in 1999. (29) Initially it was defined as negative test results for HBsAg but findings of HBV DNA in the liver whether or not DNA is detectable in the serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)

In addition, serum determination is adequately standardized and has adequate sensitivity. (31, 32) The viral load is usually less than 200 IU/mL, and in more than 90% of cases it is 20 IU/mL. (33) Basic indicators for OBI are a negative test for HBsAg plus findings of HBV DNA in serum. (30, 31) Nevertheless, the difficulty and risks of taking a liver biopsy to identify HBV DNA and lack of standardization for liver DNA, led to its replacement with testing for serum DNA. (31, 32)
that are different from those of seronegative patients. (36) Expression of interferon gamma (IFN-γ) of HBV-specific T cells is lower in seropositive patients. (36) Because of other characteristics seen in animal models of OBI, it is presumed that seropositive and seronegative patients have different forms of infection (37, 38). The majority of OBI patients (80%) are seropositive. (34)

According to the EASL, OBI is typical of the fifth phase of chronic HBV infection and is characterized by the loss of HBsAg while tests for anti-HBc remain positive with or without antisurface antibodies. (30) In these patients, cDNA is responsible for the OBI. (30-35) The detection of DNA during the serological window period of acute infection, when HBsAg is negative, is a "false occult HBV infection". (30)

The consequences of an OBI include the possibility of transmission of infection by transfusions, induction of hepatocellular carcinoma and reactivation of the infection resulting from any type of immunosuppression. (31, 37) For immunocompetent individuals, OBI is harmless, but when it reactivates, the typical markers of a manifest infection reappear. (38) Initial examinations to investigate OBI are tests for HBsAg and total anti-HBc. By definition, the HBsAg test must be negative. Regardless of the result of the total anti-HBc test, HBV DNA must be investigated. However, to avoid delays in diagnosis, these tests must be done simultaneously. If the OBI criteria are met, the diagnosis is established. (30) If all tests are negative, the patient is susceptible and must be vaccinated against HBV. (39-41)

OBI is asymptomatic, so it should be suspected and investigated in high-risk patients including:

- Those infected with human immunodeficiency virus (HIV) and/or chronic hepatitis C.
- Those who are immunosuppressed.
- Those who have hepatocellular carcinoma.
- Those who are on hemodialysis.
- Those who have cryptogenic cirrhosis.
- Those who have chronic liver disease whose cause has not been identified.
- Those who have received a transplant or are scheduled for transplantation.
- Those who will receive immunosuppression of any kind. (42)

Patients with hepatitis C (HCV) who also have OBI are at risk because elimination of HCV with direct-acting antivirals can lead to reactivation of HCB and produce acute liver failure whose severity can vary even to the point of causing death. (43 - 45) In 2016 the Food and Drug Administration (FDA) issued an alert after registering 24 of these cases between 2013 and 2016. (46) Reactivation was identified in a timely manner in half of these patients, and they were immediately treated with tenofovir/entecavir which resulted in clinical improvement and decreased viral load. The other patients received treatment late, and two died while one underwent liver transplantation. (46) Because of the potential consequences, the FDA recommends that all patients under treatment for chronic HCV infection should be tested for HBV DNA and their liver profiles should be closely monitored. These patients should consult a physician immediately if they develop symptoms of liver damage such as jaundice, discomfort, and fever. If reactivation has begun, they should receive urgent treatment with tenofovir or entecavir. (47)

**ISOLATED ANTI-HBC**

The core antigen is the most immunogenic of all the internal components of HBV. (48) Antibodies against the core antigen are produced in all infected patients, regardless of whether or not they resolve the acute infection. (48) As previously mentioned, in acute infections the antibody is IgM whose levels decrease progressively as the infection resolves. They are replaced by IgG antibodies which can persist throughout the patient’s life. (49, 50) The most reliable serological markers of HBV infection are called its epidemiological markers. (49)

The finding of total anti-HBc antibodies, without HBsAg and antisurface antibodies, is called isolated anti-HBc. (50, 51) Isolated anti-HBc is found mainly among high risk groups including users of intravenous recreational drugs, HCV patients, HIV patients, those on hemodialysis, solid organ transplant recipients and pregnant women. (51)

Prevalence of anti-HBc varies from 1% to 32%, (50) and identification of it represents a challenge for the clinician since it can correspond to various situations: (51)

1. A resolved infection (most frequent);
2. A false positive (frequent in people from regions with low prevalences of HBV) (50, 51)
3. An acute infection in which the IgM anti-HBc explains the positivity of the total anti-HBc.
4. A chronic infection with low levels of replication. This group has the highest risk when they require immuno-suppression. (52)
5. Coinfection with HCV or HIV. (50, 53-60)

The mechanisms involved are explained below.

**False Positives**

Although immunoassays currently used to identify the total anti-HBc are highly specific, errors that produce incorrect results can occur. (50) Therefore, it is recommended that results be confirmed with a second serum sample. (50, 61)
False positives can be identified with an enzyme immunoassay even though it is less specific than a radioimmunoassay. (62, 63) This is important because radioimmunoassays are not available in all laboratories so cannot always be used as back up tests. (50, 51)

**HCV and HIV Coinfections (54-60)**

Co-infections with HCV or HIV can interfere with HBV replication and the host’s immune response by inducing negative regulation of HBV genes or by modulating the immune response against HBV. (50)

Reciprocal inhibition has been demonstrated between HBV and HCV. (54, 55) The central proteins of HCV inhibit replication of HBV and synthesis of HBsAg. (55, 57) In HIV infections, the only marker of an HBV infection is likely to be isolated anti-HBc, (50, 58) so testing for HBV DNA should be included when investigating HBV in a patient with HIV.

The evaluation of a patient who has tested positive for anti-HBc is shown in Figure 2. (61)

A synthesis of the meaning of the isolated anti-HBc is shown in Table 3.

**REACTIVATION OF INFECTIONS**

HBV reactivation in individuals who had apparently been cured of acute infection but who then received immunosuppressants was described more than 50 years ago. (64, 65) Immunocompetence controls HBV, but when it is lost, the virus can reactivate. (66, 67) Loss of immunocompetence may be spontaneous or induced by immunosuppressants. (67, 68)

Scientific associations have different recommendations about which HBV tests should be performed before starting immunosuppression (Table 4). (28, 68-70)

These differences are probably due to the lack of prospective studies and the varying prevalences of HBV in different parts of the world. (69) In the Asian Pacific guide, total anti-HBc is not requested, because that region’s HBV prevalence is very high: around 30%. (71) Based on published evidence, all patients undergoing chemotherapy or
Table 3. Isolated anti-HBc

<table>
<thead>
<tr>
<th>Resolved Acute Infection IgG</th>
<th>Immune Window Period IgM</th>
<th>Chronic Infection IgG</th>
<th>Coinfection with HCV or with HIV OIB</th>
<th>False Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg</td>
<td>Anti-HBc</td>
<td>Antisurface</td>
<td>HBV DNA</td>
<td>HBsAg</td>
</tr>
<tr>
<td>CDC</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>AASLD</td>
<td>Yes, high risk</td>
<td>Yes, high risk</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>EASL</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>APASL</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ASCO</td>
<td>Yes, high risk</td>
<td>Yes, high risk</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>AGA</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

AASLD: American Association for the Study of Liver Diseases; AGA: American Gastroenterological Association; APASL: Asian Pacific Association for the Study of the Liver; ASCO: American Society of Clinical Oncology; CDC: Centers for Disease Control and Prevention

immunosuppression should have HBsAg, total anti-HBc and antisurface antibody tests. If they have only test positive for anti-HBc, a test for HBV DNA should be done. (72-74) These recommendations are also valid for patients who have concomitant diseases that impair immunity. (72-74) The risk of reactivation depends on the serological profile and the type of chemotherapy. Immunosuppression schemes that most frequently induce reactivation are those that include rituximab. This chimeric monoclonal antibody against the CD20 protein is mainly expressed in the plasma membrane of B cells. (74-77) Recently, the AGA published guidelines on immunosuppression and HBV infections whose recommendations are based on stratification of the risk of reactivation. (68, 69) Those recommendations are presented in Figures 3, 4 and 5. (72)

If a patient tests positive for HBsAg, and antiviral prophylaxis is not used, the risk of reactivation is 30% to 80%. These patients should be treated with adefovir or entecavir. (73) The origin of reactivation is the cDNA, but as the amount of antisurface antibodies increases, the risk of reactivation decreases. (68, 69) One study found HBV did not reactivate in any of ten patients whose antisurface antibody levels were above 100 IU/mL. (74) Reactivation is identified by changes in DNA and ALT. (68) In patients who are HBsAg positive who test positive for anti-HBc and HBV DNA, reactivation is confirmed if the amount of HBV DNA is raised 1 Log (10 times) or if the test for DNA is positive when it was negative previously. (69, 76) The ALT may be three or more times the normal upper limit. When the amount of these enzymes increases, patients prognoses worsen. (76) Clinical manifestations of reactivation range from asymptomatic to acute liver failure and death. (76, 77) The recommendation of the AGA is to provide prophylactic treatment rather than simply monitoring DNA. (68)

When monitoring indicates reactivation is likely the behavior is called deferred treatment. (68) Reactivation can also occur in patients who have had resolved acute infections with serologic evidence of functional cure (negative HBsAg, positive antisurface with positive or negative anti-HBc) (75-77). HBV reactivates in 16% of these cases when they undergo chemotherapy containing rituximab. (75) For patients with resolved infections, the recommendation is to monitor viral DNA every 4 weeks and if it becomes positive, therapy for HBV should be administered. (76) A recent study compared monitoring this type of patient with treating them prophylactically. (78) At 18 months of follow-up, the virus had reactivated in 3/28 patients in the monitoring group but had not reac-
High risk of reactivation (over 10%)

- HBsAg positive/anti-core positive
  - Patients who take medications such as rituximab and ofatumumab that deplete B cells
  - Antiviral prophylaxis for at least 12 months after immunosuppression is suspended

- HBsAg positive/anti-core positive or HBsAg negative/anti-core positive
  - Derivatives of anthracycline such as doxorubicin and epirubicin
  - Four or more weeks of 10 to 20 mg/day of prednisone or equivalent, or more than 20 mg/day of prednisone or equivalent

- HBsAg positive/anti-core positive
  - Antiviral prophylaxis for at least 6 months after immunosuppression is suspended

Moderate risk of reactivation (1% to 10%)

- HBsAg positive/anti-core positive
  - Patients who take TNF inhibitors such as infliximab, etanercept, adalimumab and certolizumab or other biologicals including abatacept, ustekinumab, natalizumab and vedolizumab

- HBsAg positive/anti-core positive
  - Patients who take low doses of steroids (less than 10 mg/day) for four or more weeks
  - Patients who take tyrosine kinase inhibitors such as imatinib and nilotinib

- HBsAg negative/anti-core positive
  - Patients who moderate or high doses of steroids (10 to 20 mg/day or more than 20 mg/day) for four or more weeks or who take derivatives of anthracycline such as doxorubicin and epirubicin
  - Antiviral treatment for a least 6 months after suspension of immunosuppression

**Figure 3.** Patients with a high risk of reactivation of HBV. Modified from: American Gastroenterological Association. Gastroenterology 2015; 148 (1): 220.

**Figure 4.** Patients with moderate risk of reactivation of HBV. Anti-TNF: inhibitor of tumor necrosis factor. Modified from: American Gastroenterological Association. Gastroenterology 2015; 148 (1): 220.

tivated in any (0/33) of those who received prophylactic therapy with tenofovir. (78) Since this difference was not statistically significant, a study with a larger sample size is needed to determine which is the best option or whether there are any differences. In the latter case, the choice will depend on the cost of the drugs versus the cost of measuring DNA every 4 weeks.

For patients who have infection markers, the recommendation is antiviral drugs that target HBV. Adefovir and entecavir are recommended because of their low capacities of inducing HBV resistance. Despite the high risk of reactivation, the availability of clinical practice guidelines on the subject and HBV research among oncologists in the United States is suboptimal. (68, 75, 79)
OTHER MARKERS OF HBV INFECTION

Hepatitis B Core Related Antigen (HBcrAg)

HBcrAg is a new marker of HBV infection. First described in 2002, it is being used for monitoring and establishing prognoses. (80, 81) Its serum concentration has an excellent correlation with HBV DNA in the blood, but it is superior to HBV DNA for determining viral replication and intrahepatic cDNA. (82) HBV DNA and HBsAg in blood are a reflection of intrahepatic cDNA, but HBcrAg is more sensitive than these classic markers. Seventy-eight percent of patients who have test negative for DNA due to antiviral treatment still test positive HBcrAg. (83) Another study by Lai et al. found that 51% of patients who tested negative for HBV DNA had liver biopsies that tested positive for cDNA. (84)

Similarly, other studies have shown that there is no correlation between the disappearance of serum DNA and the disappearance of intrahepatic cDNA. (80) In contrast, HBcrAg is a better reflection of cDNA. (80) Patients whose tests are negative for HBsAg, positive for anti-HBc, negative for DNA and positive for HBcrAg positive while undergoing chemotherapy have a reactivation rate that can reach 40%. (85) Due to the greater sensitivity of HBcrAg as a marker of cDNA, it is considered to be a very promising new tool which could allow better monitoring of the treatment of chronic HBV infections and which could become very useful for monitoring reactivation of HBV in patients with OBI. (80)

Conflicts of Interest

None.

Acknowledgements

The authors are indebted to Dr. Sandra Rubiano and Dr. Walter Chávez, excellent internists and teachers from Colombia, for their critical reading of the initial manuscript and for their recommendations which significantly improved this study.

REFERENCES

5. Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B virus immunopathology, model systems, and


57. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084-6.


57. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084-6.


